The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
Vikki Velasquez is a researcher and writer who has managed, coordinated, and directed various community and nonprofit organizations. She has conducted in-depth research on social and economic issues ...
However, Recursion’s revenue fell short, reaching only $5.18 million compared to the expected $16.95 million. In another development, Recursion announced the registration of 7.1 million shares for ...
Hosted on MSN
Jim Cramer on Recursion: “It is so low that it comes in under the category of speculative”
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback